Ad

Showing posts with label lyme connecticut. Show all posts
Showing posts with label lyme connecticut. Show all posts

Saturday, December 15, 2012

Cannot Stop Thinking of the Loss In Connecticut. Love.


Dedicated to the families who lost children in Connecticut today
December 14, 2012
Original - by Natasha Call





WHERE TO BEGIN.  WHERE TO END.
Picture









































Where to begin.  Where to end.
Your baby moving and growing safely in your womb.   Love.  Safe.  Nurturing.
Beginning at the opening of life.  Development.  Fascinating.  Amazing.
New life in your arms.   Miracle of birth.  Safely in your arms.  Happiness.  Euphoria.



Where to begin.  Where to end.
Speaking in babbles and bubbles until the first word is spoken.  Laughter.  Anticipation.  Appreciation.
Beginning the intellectual growth to full sentences.  Prideful.  Share.  Happiness.  Unconditional love.
Safely telling you when something isn't right or something is great.  Praise.  Love.  Relief.

Where to begin.  Where to end.
The life you brought to this earth only an arms distance away.   Incredible.  Safe.
Beginning to crawl and then walk away from that arms length.  Pride.  Fear.  Love.  Smile.
Distance grows, but safely an eyesight away.   Adoration and love.  Amazing.Where to begin.  Where to end.
Giving distance as school starts.  Heart hurts.  Crying.  Missing.  Praying.  Loving.  Longing.
Beginning independence.  Proud.  Sharing.  Deep worrying.  Encouraging.  Anticipating.
Shares experiences of learning and growth.  Magnets on fridg.  Crayon on wall.  Adore.  Amazing Love.

Where to begin.  Where to end.
Distance  again as I take you to school to learn and have fun.  Smile.  Love.  Run.
Beginning to drop off.  Think of your sweet smile.  I love you.  I adore you.  I encourage you.  Kiss good-bye.
Angels prepare for your entry into heaven as I leave.  Love.  Look at the magnets on the fridg and the crayon on the wall.

Where to begin.  Where to end.
Call from school.  Alarmed.  Your life from conception running in my mind.  Oh my love!  Hurry!  Worry.
Ending?  Where are you?  My baby.  My child once safe in womb, once babbling, crayon on wall, magnets on fridg.
Gone from your tiny shell?  Angels surround.  Gone?  No Graduation?  No Wedding?  No Babbling grandbabies?

Where to begin.  Where to end.
Praying.  Hold you one last time. Love.  Birth. Crawl.  Walk. Talk. Crayon on wall.  Magnets on fridg.  Kiss your forehead.
Beginning.  A new angel now in heaven.  My baby had love.  My baby had me.  I had my baby.  Mine forever.
Gone only from sight.  Never to forget.  Safe again.  Beginning to end to beginning. Love ever after.   Just a new chapter.



Where to begin.  Where to end.
Fly free my little angel.  No more fear my dear.  Love.  All encompassing love, light.  Heaven your new playground.
Beginning.  Play with your angel friends.  Run.  Fly.  Explore Heaven.  Please don't forget my love.  Memories forever.
Visit.  Kiss my cheek.  My baby angel.  Unconditional love.  One day we will be together forever.   Another new chapter.


by Natasha Call

Picture
source: http://www.oneutahmom.com/

Thursday, May 17, 2012

What Did The FDA Rule On Testing New Drug For Chronic Lyme?


So, if there isn't late-stage or chronic Lyme disease, why would the FDA rule on a new drug to treat chronic Lyme?  I have chronic Lyme or late-stage Lyme and we are literally dying to receive a drug treatment.  I have scoured the Internet and the following is the only information I could find.  I could not find the ruling anywhere.

----------------------------------------------------------


FDA to Rule on Testing New Drug for Chronic Lyme

Published 10:15 a.m., Monday, April 2, 2012


Researchers led by Time for Lyme grantee, M. Karen Newell-Rogers, Ph.D, have submitted a pre-IND briefing document to the US Food and Drug Administration, a preliminary step toward developing proposals for clinical testing of a new drug that could one day end the suffering of those with chronic, or long-term Lyme disease.

Stamford, CT (PRWEB) April 02, 2012

“To our knowledge this is the first novel drug candidate that has been proposed for study in the treatment of chronic Lyme Disease post-infection in some time,” said a representative of Viral Genetics, that submitted the proposal for its drug candidate, VGV-L, to the FDA. A response is expected in April.


Tests led by Dr. Newell-Rogers, a professor at Texas A&M Health Science Center College of Medicine and Scott & White Hospital, and a scientific advisor to Viral Genetics, have been conducted for over two and a half years. The results were submitted this month to the FDA, along with a protocol for a proposed human clinical trial designed under the guidance of a leading Lyme clinician at one of the nation’s top medical centers. Testing to date was conducted by Dr. Newell-Rogers with significant contributions from other clinicians at the University of Colorado, Texas A&M Health Science Center and Scott & White Hospital in Texas.

Prior research had established the insight that certain immune characteristics may contribute to whether a person is susceptible or resistant to the development of chronic inflammation as a result of infection. Dr. Newell-Rogers theory proposes a “targeted” peptide to replace or remove the self-peptides and restore a healthy immune response in patients.

Much of the funding for the pre-clinical studies leading to the FDA filing was provided by Time for Lyme, acting in concert with Richard Gerstner, the ex-IBM Executive VP who saw the potential applicability of Dr. Newell’s work, to Lyme disease.

Time for Lyme has raised over $5 million since its founding in 1998 to fund research on Lyme and other tick-borne diseases at esteemed institutions across the U.S., including the establishment and endowment of Columbia University Medical Center’s Lyme and Tick-borne Disease Research Center.

“Time for Lyme is focused on its clear and single mission of promoting research into Lyme and tick borne diseases,” said Peter Wild, executive director of the organization. “At present there is no recognized treatment for Lyme once it has developed into its chronic, long-term state. We are hopeful that Dr. Newell-Roger’s work will provide the solution that long-term Lyme disease sufferers have been hoping for, for decades.”





Press Release
Source: Viral Genetics, Inc.
Viral Genetics Publishes March 2012 Monthly Letter to Shareholders.
Cites Pre-IND Filing with FDA for Lyme Disease, Other Drugs in Pipeline & Progress in Algal BioFuel Subsidiary, VG Energy
Business WireSan Marino, CA (PRWEB) March 14, 2012
Viral Genetics (Pinksheets: VRAL.PK - News) today published its March 2012 Letter to Shareholders. Providing updates on the company’s progress, the letter discusses the recent Pre-IND filing for its Lyme Disease drug candidate, notes other drugs in the pipeline that have developed out of the company’s Metabolic Disruption Technology Platform, and talks about progress in proving the efficacy of the yield enhancement in the company’s algal biofuels subsidiary, VG Energy.
The letter is available on the company’s website at http://www.viralgenetics.com/shareholder-letters/Letter-to-Shareholders-Mar-12.PDF.
About Viral Genetics, Inc.
San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com.
About VG Energy
VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc. Using its Metabolic Disruption Technology (MDT), Viral Genetics' cancer research led to discoveries with major consequences in a wide variety of other industries, including production of biofuel and vegetable oils. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. Application of MDT technology to the biofuel industry could potentially allow it to overcome its major obstacle in the area of production efficiency: namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit www.vgenergy.net.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical trials, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests including clinical trials on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.’s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved. 
Contact:BlueWater Advisory Group, LLCBryan Crane, 805-294-3723
Contact:Viral Genetics, Inc.Haig Keledjian, 626-334-5310 
Click here to return to our Press Release selection page. 

Monday, July 11, 2011

Lyme Disease IS A U.S. Government-Created Bioweapon. Now Governments Deny The Existence Of The Epidemic.

Is Lyme Disease A Bioweapon Created By The United States?


Biochemistry of Lyme Disease: Borrelia burgdorferi Spirochete/Cyst 
by Prof. Robert W. Bradford and Henry W. Allen


Listing 2: History of Lyme Disease

1900
Effective antisyphilitic, Salvarsan, (syphilis, a spirochete disease) discovered by Paul Ehrlich, MD.

1908
Ehrlich awarded Nobel Prize for the arsenic-containing compound to treat syphilis.

1952/2004
Highly classified US Government animal disease research laboratory, Plum Island, in close proximity to Lyme, CT.

1974
First Lyme symptoms, 14-year old boy, Lyme, CT.

1975
Lyme disease first recognized by Allen Steere, MD, in Lyme, CT.

1982
The causative Lyme spirochete was discovered by Dr. Willy Burgdorfer.

1983
Borrelia burgdorferi was named after Dr. Willy Burgdorfer.

2003
American Biologics' Bradford Variable Projection Microscope (BVPM) images of Lyme spirochete and cyst forms.

2004
Dr. Robert Bradford, through the Bradford Research Institute (BRI), an independent research entity, funded by American Biologics, is the developer of Bismacine,TM a chemical compound of bismuth. This formulation has shown to be effective at the Ingles Hospital against the spirochete and cyst forms of the Lyme organism.

© 2004 BRI

more...

Biochemistry of Lyme Disease: Borrelia burgdorferi Spirochete/Cyst 
by Prof. Robert W. Bradford and Henry W. Allen


Once the cause of Lyme disease was known, it seemed that a treatment modality would soon follow and the problem would be solved. Unfortunately, as history has shown, this was not to be the case...

...Spirochetes in general are difficult to treat for several reasons: They have the ability to burrow into or between cells and hide, gaining protection from the immune system. Both Bb and Treponema pallidum, the causative agent for syphilis, have highly unusual outer membranes, and the molecular architecture of these membranes is responsible for their ability to cause persistent infection. 

...also has a three-layer cell wall, helping to determine the spiral shape of the spirochete. This distinctive cell wall resembles those of Gram-negative bacteria, although Bb does not stain Gram-negative but is stained by silver stains (containing silver nitrate). This characteristic may be related to the purported treatment of Lyme disease by colloidal silver.

...a single flagella, attached to each end of the spirochete, running the length of the organism and surrounded by it. This feature is significant in relation to immune protection, since most bacterial flagella are highly antigenic. Still another difference in Bb structural architecture is a clear gel-like coating surrounding the bacteria, giving it protection from the immune system.

....is one of the most immuno-suppressive infectious agent, affecting cellular immunity, humoral immunity, and natural killer (NK) cell population...

...A typical cell wall reproduction time for Streptococcus or Staphylococcus is less than 20 minutes, while the total reproduction time of Bb is from 12-24 hours. Most antibiotics inhibit the formation of cell walls and are effective only when the bacteria are dividing with the formation of new cell wall. With the slow replication time of Bb, an antibiotic would have to be present 24 hours a day for one year and six months to be present during the cell wall reproduction period....

There are basically two mechanisms by which Bb can survive within the host and remain for long periods of time, unknown by the victim. Because of these processes, a person infected by Bb can remain unsymptomatic for long periods of time and then suddenly, without warning, begin to experience symptoms once again. One of these mechanisms involves the invasion of tissues by the spirochete. The tip of the organism has the ability to bind to cells, spin and twirl until it stimulates the cells own enzymes to digest a part of the membrane, finally allowing entry. Once inside, the spirochete results in either the death of the cell or takes up residency within. It may lie dormant for years, protected from both the immune system and the action of antibiotics. 

...Some spirochets become coated with fragments of B-cell membrane and escape detection by the immune system by masquerading as a B-cell. Most of the antigenic proteins in Bb (those in other bacteria mark the microorganism for destruction by the immune system) are found on the inside of the inner membrane where they cannot contact those WBC that detect invaders...

...a second strain having different surface antigens will take up residence in a different tissue where it escapes detection and survives. For these reasons and others, it becomes apparent that this particular spirochete has evolved disguises and biological techniques to guarantee its survival and thwart any attempts to circumvent it...

...It has been demonstrated that Nitrous Oxide (NO) is toxic to Borrelia burgdorferi, the causative organism of Lyme disease. Therefore, any inhibitor of PDE-5 is a potential therapeutic agent for Lyme disease. Inhibitors of PDE-5 in common use today are the drugs sildenafil (more commonly known as Viagra), Levitra, and Cialis. Whether these drugs act therapeutically against the Lyme spirochete has not been demonstrated clinically and remains unknown...

...is one of the most immunosuppressive infectious agents known and, as a result, many secondary infectious agents are found...


Listing 4: Inhibitors of Borrelia burgdorferi (Bb) and its Toxin
Inhibitor
Glycyrrhizic Acid (Licorice Root) Biorizin™
Glutamylglutamate (Glu-Glu Dipeptide)
Nitrous Oxide (NO) (Arginine Stimulates Production)
Bismacine™
Chromocine™
Silver Ion
Inhibits
Toxin
Toxin
Bb
Bb
Bb
Bb
© 2005 BRI 



Major Diseases Linked to Lyme Spirochete (Lyme Disease)

Lyme Spirochete Found in the Brain of MS Patients
The causative organism of Lyme disease, Borrelia burgdorferi, has been found in the brains of many victims of multiple sclerosis (MS). The antibiotics minocycline, tinidazole, and hydroxychloroquine are reportedly capable of destroying both the spirochetal and cyst form of Bb. Because of this apparent correlation, it is proposed that double-blind clinical trials be performed to confirm this finding.17 (See Listing 5.)

Listing 5: Lyme Disease Linked to Four Major Diseases
Multiple Sclerosis, Alzheimer's, Systemic Scleroderma and Arthritis

ALZHEIMER'S 
The spirochete 
Borrelia burgdorferi has been found in the brain of many Alzheimer patients. Also in the brain, antigens and genes of Bb have been co-localized with beta-amyloid deposits.



MULTIPLE SCLEROSIS 
The spirochete 
Borrelia burgdorferi (Bb) has been found in the brain of many multiple sclerosis (MS) patients along with amyloid deposits. MS has been linked to Lyme disease both seasonally and by location.



SYSTEMIC SCLERODERMA 
The spirochete 
Borrelia burgdorferi has been found in the blood in systemic scleroderma. Treatment with antibiotics effective against Bb returned the skin to normal.



LYME-INDUCED ARTHRITIS 
Only certain strains of Bb are capable of causing the symptoms of arthritis.

http://www.townsendletter.com/FebMar2006/lyme0206.htm
© 2005 BRI



US Government Admits Lyme Disease Is A Bioweapon

The existence of the Lyme disease epidemic is officially covered up in the UK, its myriad presentations 
routinely misdiagnosed as everything from "M.E." to MS to hypochondria. This is the first admission by a 
US government body that the cause is an incapacitating biowar agent

SAN ANTONIO (AP) -- The $10.6 million Margaret Batts Tobin Laboratory Building will provide a 22,000-
square-foot facility to study such diseases as anthrax, tularemia, cholera, lyme disease, desert valley 
fever and other parasitic and fungal diseases. The Centers for Disease Control and Prevention identified 
these diseases as potential bioterrorism agents.".

 http://www.msnbc.msn.com/id/10039154/

So, for the first time, a
US government body admits that Lyme disease is a biological warfare agent. 
This is the reason that hundreds of thousands of men, women and children around the world have 
been left to rot with wrong diagnoses, or have had their Lyme disease acknowledged but been told
that it is an "easily-treated" disease, given 3 weeks' antibiotics, then told to shove off when their 
symptoms carried on after that.

In Britain the existence of the epidemic is denied completely, and virtually no effort made to warn or 
educate the public about the dangers of ticks, which carry the bacteria Borrelia burgdorferi.

The Borrelia genus has been a subject of biowar experimentation at least as far back as WW2, 
when the infamous Japanese Unit 731, which tortured and experimented on live prisoners, studied it.

The reality is, Lyme disease is for many a chronic, horrendous, incapacitating disease 
producing crippling fatigue, constant pain, loss of memory, possible paralysis, psychosis, 
blindness and even death.


It was an ideal biowar agent because it evades detection on routine tests, has an enormous range of 
different presentations, and can mimic everything from ADHD to multiple sclerosis to carpal tunnel 
syndrome to rheumatoid arthritis to chronic fatigue syndrome (M.E.) to lupus to schizophrenia. Enemy 
medical staff would never know what had hit them, nor even that ONE illness had hit their population,
rather than an unexplained rise in dozens of known conditions.

Honest doctors and scientists who tried to treat or research Lyme disease according to ethical principles 
have been viciously persecuted by government-backed organisations in the US, Europe and elsewhere. 
Many specialists in the US were threatened with loss of their license or had anonymous, false allegations 
sent to the medical board, which tied them up in mountains of paperwork and legal fees...some were forced 
out of medicine or even driven to suicide.

Instead, medical disinfo agents, most of whom have a background in military/biowarfare units, such as 
Dr Allen Steere, Mark Klempner, Philip Baker, Edward McSweegan, David Dennis, Alan Barbour etc were 
enabled to assume top positions in Lyme research , CDC, NIH etc from where they issued false information , 
covering up the true seriousness and chronic nature of the disease, and comdemned untold numbers to a 
---------------------------------------------------------------------------------------------

If you have read the information above,  you may find it interesting, but chalk it up to conspiracy hype.
However, as a person who is living with late-stage Lyme disease, I can tell you that it is not blown out
of proportion and that it is not conspiracy hype.  

I was diagnosed with bi-polar disorder, then chronic fatigue, fibromyalgia, early Alzheimer's, Parkinsons,
Multiple Sclerosis and many other illnesses before they diagnosed me correctly with Lyme.  Over those
many long years, I was treated with very strong medications that will affect me for the rest of my life.
Additionally, the damage done by the Lyme will also affect me for the rest of my life.  It affects the
neurological system and migrates, creating symptoms that mimic many different diseases.

Medical bills get out of control.  The government created it and so they should pay for the many, many
treatments and the disability that comes with it.

I am posting this information so that there is more that may understand the disease, its origins, and may
find the treatments they need to have a life that is more fulfilling and less painful, along with peace-of-mind
from knowing what you actually have. 

Thanks for reading!